Blog Archives - Page 14 of 15 - TrialAssure

trialassure clinical trial transparency news

This week in transparency news: September 8-14, 2018

by Staff Writer | September 2018

Posted in Blog

Read More

Feature image

This week in transparency news: August 25 – September 7, 2018

by Staff Writer | September 2018

Posted in Blog

Read More

trialassure clinical trial transparency news

This week in transparency: August 18 – August 24, 2018

by Staff Writer | August 2018

Posted in Blog

Read More

Feature image

This week in transparency news: August 10 – August 17, 2018

by Staff Writer | August 2018

Posted in Blog

Read More

Outsourcing-Pharma released a State of the Industry report that sheds light on the global pharmaceutical industry. One of the key findings in the report showed that more than half of survey respondents believe that industry initiatives will lead to greater transparency. The report points to a new pilot program launched earlier this year by the FDA to increase transparency. Clinical Trial Transparency Software client feedback

This week in transparency news: August 4 – August 9, 2018

by Staff Writer | August 2018

Posted in Blog

Read More

Should people share their DNA for drug development purposes? – USA Today Many people don’t realize that sharing a DNA sample with Ancestry.com, 23andMe and others can result in their data being shared. However, this week, the companies pledged that they would disclose when data is shared with corporations or the government. With a $300 million investment by GSK in 23andMe, they state that approximately 80 percent of customers have agreed to share their DNA data. This data is being de-identified before it is shared.

This week in transparency news: July 28 – August 3, 2018

by Staff Writer | August 2018

Posted in Blog

Read More

Policy 0070 submissions pending suspension in Europe – DIA Communities Due to EMA’s relocation from London to Amsterdam, the “launch of new procedures (related to clinical data publication under Policy 0070) will be temporarily suspended already as of 1 August 2018,” according to an email shared by Melanie Carr, Head of Stakeholders and Communication Division and Head of Corporate Stakeholders Department ad interim, European Medicines Agency (EMA). It is noted that all redaction proposal packages submitted after July 31st will be temporarily suspended. A press release with full details is said to be released next week.

This week in transparency news: July 21 – July 27, 2018

by Staff Writer | July 2018

Posted in Blog

Read More

Policy 0070 submissions pending suspension in Europe – DIA Communities Due to EMA’s relocation from London to Amsterdam, the “launch of new procedures (related to clinical data publication under Policy 0070) will be temporarily suspended already as of 1 August 2018,” according to an email shared by Melanie Carr, Head of Stakeholders and Communication Division and Head of Corporate Stakeholders Department ad interim, European Medicines Agency (EMA). It is noted that all redaction proposal packages submitted after July 31st will be temporarily suspended. A press release with full details is said to be released next week.

This week in transparency news: July 14 – July 20, 2018

by Staff Writer | July 2018

Posted in Blog

Read More

bioethics international good pharma scorecard gps disclosure clinical trial transparency trialassure

This week in transparency news: July 7 – July 13, 2018

by Staff Writer | July 2018

Posted in Blog

Read More

The U.S. Senate had voted in favor of an opioid bill that expands Open Payments to include payments made to Nurse Practitioners, Physician Assistants, Nurse Midwifes, Nurse Anesthetists, and Clinical Nurse Specialists, in addition to current physician reporting requirements. This will go into effect beginning January 1, 2022. Inconsistent Clinical Trial Disclosure and Lack of Compliance Across Big Pharma

This week in transparency news: June 30 – July 6, 2018

by Staff Writer | July 2018

Posted in Blog

Read More

Get in Touch